DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of ...
DBV Technologies S.A. (NASDAQ: DBVT) is a clinical-stage biopharmaceutical company headquartered in France that focuses on advancing epicutaneous immunotherapy—treatments delivered through the skin—using its proprietary VIASKIN platform. The company’s core concept is that controlled, skin-based administration of allergen-containing formulations can help the immune system build tolerance while aiming to reduce ...DBV Technologies S.A. (NASDAQ: DBVT) is a clinical-stage biopharmaceutical company headquartered in France that focuses on advancing epicutaneous immunotherapy—treatments delivered through the skin—using its proprietary VIASKIN platform. The company’s core concept is that controlled, skin-based administration of allergen-containing formulations can help the immune system build tolerance while aiming to reduce some of the risks commonly associated with traditional oral or other allergy immunotherapy approaches.
Business and product focus. DBV’s flagship product candidate is VIASKIN Peanut, designed for the treatment of peanut allergy. As described in the supplied overview, it completed Phase III clinical trials across multiple age groups, including children (4–11), adolescents, and adults—indicating the company is working toward potential broad clinical use if regulatory and commercial steps follow. The company also has VIASKIN Milk in Phase I/II clinical development for IgE-mediated cow’s milk protein allergy, and VIASKIN Egg in preclinical development for hen’s egg allergy. Beyond these core allergy programs, DBV has described additional R&D efforts related to other immunologic conditions, reflecting a pipeline strategy built around the same delivery technology and allergen-related immune modulation.
Technology and services. DBV’s “service” is primarily research and development rather than product sales in the traditional sense of a manufacturing company. The VIASKIN patch platform typically requires specialized formulation, patch manufacturing, clinical trial operations, and ongoing regulatory-grade development processes. The bill-of-materials (BOM) and cost structure for clinical-stage biotech like DBV generally concentrates on (1) clinical supply of investigational patch devices and allergen formulations, (2) contract research organization (CRO)/clinical site costs, (3) quality systems and regulatory documentation, and (4) scientific/clinical operations and data management.
Diagnostics collaboration. In partnership with Nestlé Health Science, DBV is developing MAG1C, described as a user-friendly atopy patch test for diagnosing non-IgE mediated cow’s milk protein allergy in infants and toddlers. This expands DBV’s footprint from treatment toward diagnostic support, potentially improving patient selection and clinical decision-making.
Financial and operational context. The supplied financial snapshot indicates losses and negative profitability metrics, which is consistent with a company operating predominantly through clinical development rather than commercial revenue. For example, enterprise value and cash-flow-related ratios show negative free cash flow/operating cash flow measures (TTM), and margins are negative—typical for clinical-stage biotech companies investing heavily in trials and platform advancement.
Key people. Leadership includes Daniel Tassé (Chief Executive Officer). The company was founded in 2002 and was initially associated with pediatric expertise and a mission to improve outcomes for allergic patients.
Wishes / future direction. While specific “wishes” are not explicitly stated in the sources, the company’s strategic direction implied by its pipeline is to progress VIASKIN candidates through remaining regulatory milestones, broaden evidence across patient populations, and potentially extend the platform into additional immunologic conditions and diagnostic applications such as MAG1C—aiming to turn the VIASKIN approach into a scalable medical solution.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-146.9M
-29.2%
-5.9%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-121.2M
-13.4%
-67.8%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
12.8%
-54.9%
+67.0%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
3.67x
+157.4%
-21.9%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
